Clinical trials: Prostatic Neoplasms, Castration-Resistant
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic…
- Trial name
- NCT06126731
- Testing
- Enzalutamide 40mg, Amoxicillin 500mg, Metronidazole 400mg
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer, Prostate Cancer Metastatic
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg as a 30 minute IV infusion every 3 weeks.
- Trial name
- NCT04116775
- Testing
- Fecal microbiota transplant, Pembrolizumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Julie Graff, MD
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Prostate Cancer, Metastatic Cancer
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
- Trial name
- IRSTB030 (NCT03381326)
- Testing
- blood and FFPE sample collection
- Where
- 9 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Castration Resistant Prostate Cancer
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency…
- Trial name
- CHOMP (NCT04104893)
- Testing
- Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Metastatic Castration Resistant Prostate Cancer
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
- Trial name
- PRINCE (NCT03658447)
- Testing
- Pembrolizumab, 177Lu-PSMA
- Where
- 4 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Castration-Resistant Prostatic Cancer
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess and compare the clinical benefit rate in patients with metastatic castrate-resistant prostate cancer and poor prognostic factors treated with cabazitaxel or novel hormonal agents…
- Trial name
- NCT02254785
- Testing
- cabazitaxel, Abiraterone, Enzalutamide 160mg daily (oral)
- Where
- 15 sites in Australia, Canada
- Volunteers
- 120 people
- Sponsor
- British Columbia Cancer Agency
Castration-resistant Prostate Cancer
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
This is a safety, feasibility and pharmacokinetic study to confirm that the recommended safe dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a previous phase I study is also safe and feasible…
- Trial name
- NCT03136640
- Testing
- ModraDoc006/r
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Modra Pharmaceuticals
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
This is a Phase I/Ib study of Radium-223 in combination with Tasquinimod for patients with bone metastases from castration-resistant prostate cancer (CRPC).
- Trial name
- Radium-223 (NCT02396368)
- Testing
- Tasquinimod, Radium 223
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Castration-resistant Prostate Cancer
Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
Metastatic castration-resistant Prostate cancer (mCRPC) is a very late stage of prostate cancer with poor prognosis. Although there are several treatment strategies available for mCRPC, these drugs are not always effective for…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Drug
- Trial name
- NCT03356444
- Testing
- Abiraterone Acetate, Docetaxel
- Volunteers
- 140 people
- Sponsor
- West China Hospital
Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase II trial tests whether vidutolimod with nivolumab works to destroy tumor cells in patients with castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT05445609
- Testing
- VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Metastatic Castration-resistant Prostate Cancer
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
This is a single-arm, open, single-center clinical study to evaluate the efficacy and safety of RC48-ADC in patients with mCRPC who have progressed after NHT.
- Trial name
- NCT05955209
- Testing
- Disitamab Vedotin（RC48-ADC）
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Castration Resistant Prostate Cancer
Combination Study of AZD5069 and Enzalutamide.
ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC).
- Trial name
- ACE (NCT03177187)
- Testing
- AZD5069, Enzalutamide 40 MG
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Castration-Resistant Prostatic Cancer
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen…
- Trial name
- NCT04404140
- Testing
- Ipatasertib, Atezolizumab, Docetaxel
- Where
- 9 sites in France, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT02012920
- Testing
- Seviteronel: given orally once daily in 28 day cycles
- Where
- 23 sites in United States, Greece and 2 more
- Volunteers
- 200 people
- Sponsor
- Innocrin Pharmaceutical
Metastatic Castration-resistant Prostate Cancer
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to…
- Trial name
- NCT06100705
- Testing
- Testosterone Cypionate, Sipuleucel-T
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
Prostate Cancer
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
This is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with…
- Trial name
- eRADicAte (NCT02097303)
- Testing
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Carolina Research Professionals, LLC
Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who…
- Trial name
- ARTISAN (NCT07214961)
- Testing
- AB001
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ARTBIO Inc.
Prostate Cancer
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
The purpose of this study is to find out what effects taking ipilimumab, as an immediate or delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and their prostate cancer.
- Trial name
- NCT01804465
- Testing
- SipT Treatment, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer
GX301 is an experimental therapeutic vaccine directed against human telomerase, an enzyme playing an essential role in cancer cell proliferation.
- Trial name
- NCT02293707
- Testing
- GX301
- Where
- 24 sites in Italy, Spain
- Volunteers
- 99 people
- Sponsor
- Laboratoires Leurquin Mediolanum
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.